|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
16.09.25 - 05:30
|
CAPR Deadline: CAPR Investors with Losses in Excess of $100K Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit (PR Newswire)
|
|
|
NEW YORK, Sept. 15, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Capricor Therapeutics, Inc. (NASDAQ: CAPR) between October 9, 2024 and July 10, 2025, both dates inclusive (the "Class Period"), of the important September......
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.09.25 - 23:01
|
CAPR Deadline: CAPR Investors with Losses in Excess of $100K Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit (PR Newswire)
|
|
|
NEW YORK, Sept. 10, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Capricor Therapeutics, Inc. (NASDAQ: CAPR) between October 9, 2024 and July 10, 2025, both dates inclusive (the "Class Period"), of the important September......
|
|
|
09.09.25 - 15:24
|
Capricor Therapeutics Responds to FDA Posting of Complete Response Letter (CRL) for Deramiocel (GlobeNewswire EN)
|
|
|
SAN DIEGO, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today issued a statement regarding the U.S. Food and Drug Administration's (FDA) public posting of its Complete Response Letter (CRL) for the Biologics License Application (BLA) for Deramiocel, the Company's investigational cell therapy for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD)....
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
